Who are Candesartan+HCTZ - Phase 1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): olmesartan medoxomil + hydrochlorothiazide, if necessary, Micardis plus 80/12.5, losartan and HCTZ, Candesartan plus Hydrochlorothiazide, Fimasartan; Hydrochlorothiazide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/candesartan-hctz-phase-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Candesartan+HCTZ - Phase 1 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Candesartan+HCTZ - Phase 1 (Candesartan+HCTZ - Phase 1) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker + thiazide diuretic combination. Area: Cardiovascular.

phase 3 Angiotensin II receptor blocker + thiazide diuretic combination AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Candesartan+HCTZ - Phase 1 (Candesartan+HCTZ - Phase 1) — Novartis. Candesartan blocks angiotensin II receptors to lower blood pressure, while HCTZ is a thiazide diuretic that reduces fluid volume and sodium reabsorption.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Candesartan+HCTZ - Phase 1 TARGET	Candesartan+HCTZ - Phase 1	Novartis	phase 3	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
olmesartan medoxomil + hydrochlorothiazide, if necessary	olmesartan medoxomil + hydrochlorothiazide, if necessary	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	marketed	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
Micardis plus 80/12.5	Micardis plus 80/12.5	Heart Care Foundation	marketed	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter
losartan and HCTZ	losartan and HCTZ	InVasc Therapeutics, Inc.	marketed	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (losartan); sodium-chloride cotransporter (HCTZ)
Candesartan plus Hydrochlorothiazide	Candesartan plus Hydrochlorothiazide	Novartis	phase 3	Angiotensin II receptor blocker + Thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
Fimasartan; Hydrochlorothiazide	Fimasartan; Hydrochlorothiazide	Stendhal Americas, S.A.	phase 3	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (fimasartan); sodium-chloride cotransporter (hydrochlorothiazide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker + thiazide diuretic combination class)

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
Heart Care Foundation · 1 drug in this class
InVasc Therapeutics, Inc. · 1 drug in this class
Novartis · 1 drug in this class
Stendhal Americas, S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Candesartan+HCTZ - Phase 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/candesartan-hctz-phase-1. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab